BofA raises target for Gilead Sciences stock from USD 162 to USD 164
Published on 10/13/2026 at 12:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- BofA Securities raised its Gilead Sciences price target from USD 162.00 to USD 164.00 on October 12, 2026.
- Second-quarter 2026 revenue reached USD 7.80 billion, while reported net income was a USD 10.50 billion loss.
- Gilead Sciences stock was trading at EUR 135.47 at Lang & Schwarz on October 13, 2026, versus the Xetra close of EUR 134.50.
- Gilead Sciences is scheduled to report third-quarter 2026 results on October 22, 2026.
BofA Securities raised its price target for Gilead Sciences stock from USD 162.00 to USD 164.00 on October 12, 2026, while maintaining a Buy rating, according to Investing.com. Gilead Sciences stock was trading at EUR 135.47 at Lang & Schwarz on October 13, 2026 at 12:13 p.m. CEST, or EUR 0.97 above the Xetra close of EUR 134.50 from October 12, 2026.
Three events shaped the stock
On June 30, 2026, Gilead reported second-quarter revenue of USD 7.803 billion and a net loss of USD 10.496 billion, according to Financial Report Insights. The loss included USD 11.18 billion of acquired in-process research and development expense and a USD 1.75 billion Trodelvy impairment.
On October 6, 2026, Cognizant announced a five-year extension of its agreement with Gilead to support selected technology programs and agentic artificial intelligence tools, as reported by Fortune India.
On October 12, 2026, BofA lifted its target from USD 162.00 to USD 164.00. The change is modest, but it places commercial execution ahead of the next earnings report as the immediate test for the valuation.
What does the target raise imply?
BofA's published estimates included third-quarter Biktarvy sales of USD 3.922 billion against USD 3.908 billion consensus, according to Investing.com. That comparison matters because the second quarter combined 10.20 percent revenue growth with a large acquisition-related accounting charge.
The underlying revenue figure therefore tells a different story from the headline loss. Gilead's second-quarter revenue of USD 7.803 billion exceeded the USD 7.082 billion reported for the same period a year earlier, while the net loss reversed a USD 1.960 billion profit, according to Financial Report Insights.
Next date is October 22
Gilead Sciences is scheduled to report third-quarter 2026 results on October 22, 2026, with estimates of USD 2.18 earnings per share and USD 7.92 billion in revenue, according to Tickzen. The figures will show whether the revenue expansion visible in the second quarter is continuing after the acquisition charges.
Stock quote and valuation context
The Lang & Schwarz price of EUR 135.47 stood 0.72 percent above the Xetra close of EUR 134.50 from October 12, 2026. On the primary Nasdaq listing, Gilead's finance quote was USD 150.43 on October 12, 2026 at 4:00 p.m. ET, while its 52-week range was USD 114.02 to USD 157.29 and market capitalization was USD 186.5 billion.
For investors, the central contrast is clear: revenue grew 10.20 percent in the second quarter, but reported profitability was overwhelmed by deal and impairment charges. The October 22 results should clarify whether the commercial growth rate can keep supporting the pipeline investment.
The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.
Gilead Sciences stock facts
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- WKN: 885823
- Ticker: GILD
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 13, 2026, 12:13 p.m. CEST: EUR 135.47
- Change versus Xetra close: plus 0.72 percent
- Xetra close October 12, 2026: EUR 134.50
- Market capitalization: USD 186.5 billion (as of October 12, 2026)
- 52-week range: USD 114.02-157.29 (as of October 12, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Index membership: S&P 500 and Nasdaq 100
- Next earnings date: October 22, 2026
Market context: Market report Nasdaq Composite.
